Oligonucleotide Synthesis Market Size to grow by USD 3374.04 million between 2024-2028
According to a research report “ Oligonucleotide Synthesis Market” by Application (PCR primers, PCR assays and panels, DNA microarrays, Fluorescence in situ hybridization, Sequencing and others) End-user (Pharmaceutical and biotechnology companies, Research and academic institutes, Diagnostic laboratories, Hospitals) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3374.04 million, at a CAGR of 13.54% during the forecast period. In the rapidly expanding field of RNA-based therapeutics, custom-designed oligonucleotides are indispensable for the synthesis of mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNAs. The burgeoning development and commercialization of RNA-based drugs, including mRNA vaccines such as those produced by BioNTech for COVID-19, underscore the necessity for high-quality, sequence-specific oligonucleotides. These vaccines necessitate custom-designed mRNA sequences encapsulated in lipid nanoparticles, which are produced through oligonucleotide synthesis. Consequently, the demand for oligonucleotide synthesis is escalating, fueling the expansion of the market in focus.
Browse market data tables, figures, and in-depth TOC on “Oligonucleotide Synthesis Market” by Application (PCR primers, PCR assays and panels, DNA microarrays, Fluorescence in situ hybridization, Sequencing and others) End-user (Pharmaceutical and biotechnology companies, Research and academic institutes, Diagnostic laboratories, Hospitals) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the PCR primers segment is projected to dominate the market size in 2024
The pharmaceutical and biotechnology sector represents a significant market for oligonucleotide synthesis, driven by the increasing research and development of oligonucleotide therapeutics. Pharmaceutical companies are investing heavily in the production of chemically synthesized oligonucleotides, which offer high specificity akin to therapeutic antibodies. Notable oligonucleotide therapies include small interfering RNA (siRNA) therapy, antisense oligonucleotide therapy, micro RNA (miRNA) therapy, aptamer therapy, and CpG oligonucleotide therapy. Regulatory approvals from authorities like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have fueled the interest of pharmaceutical and biotechnology companies in the discovery and development of these innovative therapies.
By End-user, Pharmaceutical and biotechnology companies segment is expected to hold the largest market size for the year 2024
In the realm of molecular biology, PCR primers are indispensable oligonucleotide sequences, meticulously designed to bind to specific target DNA sequences, initiating the amplification process in Polymerase Chain Reactions (PCR). These primers are integral to various PCR-based applications, such as gene expression analysis, DNA sequencing, mutation detection, and genotyping. Oligonucleotide synthesis companies provide custom design and synthesis services for PCR primers, enabling researchers to specify their target DNA sequence, primer length, and other parameters. Utilizing advanced synthesis techniques, these companies ensure the delivery of high-quality, pure, and accurately synthesized PCR primers. To facilitate optimal primer design, many companies offer online primer design tools or software to researchers.
North America is forecasted to hold the largest market size by region in 2024
The North American region, with the United States at the forefront, holds a dominant position in the oligonucleotide synthesis market. Key market players, including Agilent Technologies Inc., Thermo Fisher Scientific Inc., and QIAGEN NV, based in the US, significantly contribute to the market growth. These vendors provide customized oligonucleotide products, fueling the adoption of synthetic nucleic acids in research, therapeutics, and diagnostic applications. Advanced technologies and methodologies employed by US vendors enable them to meet the escalating demand for oligonucleotides. For instance, Agilent Technologies Inc. has implemented process modifications to boost its per-cycle synthesis yield from 98% to 99.5%, thereby enhancing the overall product quality.
The Oligonucleotide Synthesis Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Oligonucleotide Synthesis Market has witnessed significant growth in recent years due to the increasing demand for Interference RNA (RNAi) and gene therapy. Oligonucleotides are short chains of nucleotides, which are the building blocks of both RNA and DNA. These nucleotides consist of a nitrogenous base, a sugar molecule (either ribose or deoxyribose), and a phosphate group. The four primary nitrogenous bases are Uracil, Thymine, Guanine, and Cytosine, while Adenine is unique to DNA. RNAi and gene therapy have emerged as promising therapeutic approaches for various diseases, including genetic disorders such as Cystic Fibrosis. In RNAi therapy, small interfering RNAs (siRNAs) are used to silence specific genes, while in gene therapy, oligonucleotides are used to deliver therapeutic genes to cells. The synthesis of oligonucleotides is typically carried out using solid-phase synthesis techniques. This involves the stepwise addition of nucleotides to a growing chain, starting with an initiator or primer. The market for oligonucleotide synthesis is driven by the genome projects, synthetic biology, and the development of new vector technologies for gene and RNA therapy. The global oligonucleotide synthesis market is expected to grow at a CAGR of over 10% during the forecast period.
Market Research Overview
The Oligonucleotide Synthesis Market encompasses the production of short, synthetic single-stranded nucleic acid molecules, including DNA and RNA, used in various applications such as Protein synthesis, RNA-induced silencing complex (RISC), Interference RNA (siRNA), Antisense therapy, Gene therapy, and Vector technologies. Oligonucleotide synthesis involves the assembly of nucleotide chains, which consist of nitrogenous bases (Adenine, Thymine, Guanine, Cytosine, and Uracil), a sugar molecule (Ribose or Deoxyribose), and a phosphate group. Oligonucleotide purification technology is crucial for removing impurities and ensuring product quality. Techniques such as Polyacrylamide gel electrophoresis, HPLC, and filtration are commonly used. Oligonucleotide modification, including backbone modifications and labeling modifications, enhances their stability, specificity, and efficacy. Major players in the market include Creative Biolabs, EnPlusOne Biosciences, and various contract service providers. Applications of oligonucleotides span from Clinical trials and Gene therapies to Diagnostics, Synthetic biology, and Therapeutics. Notable applications include Vitravene for treating Cystic Fibrosis, CRISPR for gene editing, and PCR primers for molecular testing. Oligonucleotides play a significant role in addressing genetic disorders like Charcot-Marie-Tooth disease and Down syndrome, as well as diseases like Cancer.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
